How melanoma cells evade trail-induced apoptosis View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2001-11-01

AUTHORS

Peter Hersey, Xu Dong Zhang

ABSTRACT

Key Points Several natural defence mechanisms kill melanoma cells by apoptosis. These are induced by granzyme B or interaction with members of the tumour necrosis factor (TNF) family, such as TNF-related apoptosis-inducing ligand (TRAIL). As a consequence, melanoma cells that survive in the host might do so because they have been selected for resistance to apoptosis. Resistance mechanisms include low death-receptor expression and inhibition of intracellular death pathways. Induction of p53 is important in upregulation of TRAIL death receptors in response to DNA damage, but relatively little is known about the control of constitutive expression. Fresh isolates of melanoma cells have low death-receptor expression and development of treatments that increase their expression are crucial for the success of TRAIL-dependent killing of melanoma. One of the main inhibitors of TRAIL-induced apoptosis is the inhibitors of apoptosis (IAP) family, particularly XIAP. XIAP levels are reduced after exposure to TRAIL because TRAIL induces release of a pro-apoptotic protein, SMAC/DIABLO, from mitochondria, which binds to and inactivates members of the IAP family. This represents an alternative to the classical mitochondrial death pathway, which is limited in most melanoma cells by low or absent APAF1 levels. SMAC/DIABLO release from the mitochondria of TRAIL-resistant melanoma cells is decreased, possibly due to stabilization of mitochondrial permeability by the BCL2 family. The transcription factor NF-κB and the mitogen-activated protein kinase (MAPK) and extracellular-regulated kinase (ERK) 1 and 2 pathways seem to be the principal regulators of the IAP and BCL2 family, respectively. These findings provide insights into resistance of melanoma to apoptosis and provide a framework for therapeutic approaches based on providing pro-apoptotic stimuli, as well as reducing anti-apoptotic mechanisms. More... »

PAGES

142-150

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/35101078

DOI

http://dx.doi.org/10.1038/35101078

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1021222128

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/11905805


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Apoptosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Apoptosis Regulatory Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Caspase 9", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Caspases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytochrome c Group", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "DNA Damage", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme Activation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fas Ligand Protein", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gene Expression Regulation, Neoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Killer Cells, Natural", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "MAP Kinase Signaling System", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Macromolecular Substances", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melanoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Membrane Glycoproteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mitochondria", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Models, Biological", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "NF-kappa B", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Tumor Necrosis Factor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Signal Transduction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "T-Lymphocyte Subsets", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "TNF-Related Apoptosis-Inducing Ligand", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Cells, Cultured", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Necrosis Factor-alpha", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Suppressor Protein p53", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "fas Receptor", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Immunology and Oncology Unit, Room 443, David Maddison Clinical Sciences Building, Cnr King & Watt Streets, 2300, Newcastle, New South Wales, Australia", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Immunology and Oncology Unit, Room 443, David Maddison Clinical Sciences Building, Cnr King & Watt Streets, 2300, Newcastle, New South Wales, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hersey", 
        "givenName": "Peter", 
        "id": "sg:person.01073667716.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073667716.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Immunology and Oncology Unit, Room 443, David Maddison Clinical Sciences Building, Cnr King & Watt Streets, 2300, Newcastle, New South Wales, Australia", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Immunology and Oncology Unit, Room 443, David Maddison Clinical Sciences Building, Cnr King & Watt Streets, 2300, Newcastle, New South Wales, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Xu Dong", 
        "id": "sg:person.01210116316.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210116316.18"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/22788", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011644064", 
          "https://doi.org/10.1038/22788"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35051606", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052418104", 
          "https://doi.org/10.1038/35051606"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1203489", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045600742", 
          "https://doi.org/10.1038/sj.onc.1203489"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm0298-232", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044054321", 
          "https://doi.org/10.1038/nm0298-232"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1009617727938", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045070256", 
          "https://doi.org/10.1023/a:1009617727938"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35048073", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053037482", 
          "https://doi.org/10.1038/35048073"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/83401", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032285041", 
          "https://doi.org/10.1038/83401"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2401865", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004336753", 
          "https://doi.org/10.1038/sj.leu.2401865"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/83416", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047641659", 
          "https://doi.org/10.1038/83416"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/19709", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044922946", 
          "https://doi.org/10.1038/19709"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01202725", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033853040", 
          "https://doi.org/10.1007/bf01202725"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1204140", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006396136", 
          "https://doi.org/10.1038/sj.onc.1204140"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2001-11-01", 
    "datePublishedReg": "2001-11-01", 
    "description": "Key Points Several natural defence mechanisms kill melanoma cells by apoptosis. These are induced by granzyme B or interaction with members of the tumour necrosis factor (TNF) family, such as TNF-related apoptosis-inducing ligand (TRAIL).  As a consequence, melanoma cells that survive in the host might do so because they have been selected for resistance to apoptosis. Resistance mechanisms include low death-receptor expression and inhibition of intracellular death pathways.  Induction of p53 is important in upregulation of TRAIL death receptors in response to DNA damage, but relatively little is known about the control of constitutive expression. Fresh isolates of melanoma cells have low death-receptor expression and development of treatments that increase their expression are crucial for the success of TRAIL-dependent killing of melanoma.  One of the main inhibitors of TRAIL-induced apoptosis is the inhibitors of apoptosis (IAP) family, particularly XIAP. XIAP levels are reduced after exposure to TRAIL because TRAIL induces release of a pro-apoptotic protein, SMAC/DIABLO, from mitochondria, which binds to and inactivates members of the IAP family. This represents an alternative to the classical mitochondrial death pathway, which is limited in most melanoma cells by low or absent APAF1 levels.  SMAC/DIABLO release from the mitochondria of TRAIL-resistant melanoma cells is decreased, possibly due to stabilization of mitochondrial permeability by the BCL2 family.  The transcription factor NF-\u03baB and the mitogen-activated protein kinase (MAPK) and extracellular-regulated kinase (ERK) 1 and 2 pathways seem to be the principal regulators of the IAP and BCL2 family, respectively.  These findings provide insights into resistance of melanoma to apoptosis and provide a framework for therapeutic approaches based on providing pro-apoptotic stimuli, as well as reducing anti-apoptotic mechanisms.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/35101078", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1029716", 
        "issn": [
          "1474-175X", 
          "1474-1768"
        ], 
        "name": "Nature Reviews Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "1"
      }
    ], 
    "keywords": [
      "mitogen-activated protein kinase", 
      "TRAIL-induced apoptosis", 
      "death pathways", 
      "BCL2 family", 
      "death receptor expression", 
      "Smac/DIABLO release", 
      "melanoma cells", 
      "extracellular regulated kinases 1", 
      "mitochondrial death pathway", 
      "intracellular death pathways", 
      "Smac/DIABLO", 
      "pro-apoptotic stimuli", 
      "pro-apoptotic proteins", 
      "induction of p53", 
      "transcription factor NF-\u03baB", 
      "DIABLO release", 
      "IAP family", 
      "TRAIL death receptors", 
      "protein kinase", 
      "factor family", 
      "factor NF-\u03baB", 
      "most melanoma cells", 
      "apoptosis-inducing ligand", 
      "mitochondrial permeability", 
      "death receptors", 
      "tumor necrosis factor family", 
      "kinase 1", 
      "constitutive expression", 
      "apoptosis (IAP) family", 
      "natural defense mechanisms", 
      "anti-apoptotic mechanisms", 
      "XIAP levels", 
      "resistance of melanoma", 
      "DNA damage", 
      "principal regulator", 
      "defense mechanisms", 
      "resistance mechanisms", 
      "apoptosis", 
      "necrosis factor family", 
      "TRAIL-resistant melanoma cells", 
      "mitochondria", 
      "pathway", 
      "expression", 
      "cells", 
      "NF-\u03baB", 
      "family", 
      "development of treatments", 
      "main inhibitor", 
      "fresh isolates", 
      "inhibitors", 
      "kinase", 
      "DIABLO", 
      "regulator", 
      "TRAIL-dependent killing", 
      "mechanism", 
      "protein", 
      "IAP", 
      "members", 
      "granzyme B", 
      "host", 
      "p53", 
      "upregulation", 
      "therapeutic approaches", 
      "induction", 
      "isolates", 
      "receptors", 
      "resistance", 
      "trails", 
      "inhibition", 
      "release", 
      "killing", 
      "insights", 
      "levels", 
      "ligands", 
      "interaction", 
      "melanoma", 
      "response", 
      "damage", 
      "TNF", 
      "consequences", 
      "development", 
      "stabilization", 
      "stimuli", 
      "exposure", 
      "success", 
      "control", 
      "findings", 
      "permeability", 
      "treatment", 
      "approach", 
      "alternative", 
      "framework"
    ], 
    "name": "How melanoma cells evade trail-induced apoptosis", 
    "pagination": "142-150", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1021222128"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/35101078"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "11905805"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/35101078", 
      "https://app.dimensions.ai/details/publication/pub.1021222128"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:31", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_333.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/35101078"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/35101078'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/35101078'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/35101078'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/35101078'


 

This table displays all metadata directly associated to this object as RDF triples.

320 TRIPLES      21 PREDICATES      157 URIs      138 LITERALS      36 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/35101078 schema:about N103dacf83e1d42c7929cb3baf2e01ffe
2 N15cfe3470e684f20ac4016152ec7663b
3 N240c4510ca3c4a2ea3c7db4a897c43ae
4 N25ab614802914ef1a77a956005e70d03
5 N26f76226c7f54577bf9c52ad55dfbc24
6 N3187e6700efb441cabc0e23bf9640396
7 N40617c13a25b440fb298b0fd4ec83b12
8 N452a3979ed1442848c9909c5c4501a57
9 N46cf9ce1bd93485e9320fb1513494501
10 N54f536ed1439419f814b3cfdf8927d84
11 N56583697bae348669b7dda5ed2a37d7b
12 N5dd5904df48a44c7be9550c639746c36
13 N62d44a6a6493492ba85ab50e0ec56453
14 N646cebc375d84906a31f40b69f3edf01
15 N7a964cb14e244055a836747353b61bbc
16 N81df16af004c49c4a486654993b7b183
17 N8206f0fdfac349d39a6f543d2fd9783d
18 N87822fc6b6f34b1dbc1a4f2825bd817c
19 N8b070f319e484c738f1b90e1fe9df436
20 Nb63ee6f6b47c434680d5085f9ce4f40d
21 Nba10fb5036894df6b411d4e1b6e33d77
22 Nbc84722d4e5844ab9d3cef0a4183904a
23 Nc86ef2e56d6d4b5896676fcf9128800b
24 Nddae1e5bfa474b75af7778faae9d8385
25 Ndeffe4ad6e104bff90017ef887d0bf28
26 Ndfd03d5c47804c6ea56374f89b74dbfe
27 Ne1b1a3c78a234bec8a663e8c1094290e
28 Ne708965c70a0410d837010a3794ead22
29 Nfb8fc4c58e9745cea40ddb3ace36f02c
30 anzsrc-for:11
31 schema:author N1ea7c674786d45adb6f9befa941c8135
32 schema:citation sg:pub.10.1007/bf01202725
33 sg:pub.10.1023/a:1009617727938
34 sg:pub.10.1038/19709
35 sg:pub.10.1038/22788
36 sg:pub.10.1038/35048073
37 sg:pub.10.1038/35051606
38 sg:pub.10.1038/83401
39 sg:pub.10.1038/83416
40 sg:pub.10.1038/nm0298-232
41 sg:pub.10.1038/sj.leu.2401865
42 sg:pub.10.1038/sj.onc.1203489
43 sg:pub.10.1038/sj.onc.1204140
44 schema:datePublished 2001-11-01
45 schema:datePublishedReg 2001-11-01
46 schema:description Key Points Several natural defence mechanisms kill melanoma cells by apoptosis. These are induced by granzyme B or interaction with members of the tumour necrosis factor (TNF) family, such as TNF-related apoptosis-inducing ligand (TRAIL). As a consequence, melanoma cells that survive in the host might do so because they have been selected for resistance to apoptosis. Resistance mechanisms include low death-receptor expression and inhibition of intracellular death pathways. Induction of p53 is important in upregulation of TRAIL death receptors in response to DNA damage, but relatively little is known about the control of constitutive expression. Fresh isolates of melanoma cells have low death-receptor expression and development of treatments that increase their expression are crucial for the success of TRAIL-dependent killing of melanoma. One of the main inhibitors of TRAIL-induced apoptosis is the inhibitors of apoptosis (IAP) family, particularly XIAP. XIAP levels are reduced after exposure to TRAIL because TRAIL induces release of a pro-apoptotic protein, SMAC/DIABLO, from mitochondria, which binds to and inactivates members of the IAP family. This represents an alternative to the classical mitochondrial death pathway, which is limited in most melanoma cells by low or absent APAF1 levels. SMAC/DIABLO release from the mitochondria of TRAIL-resistant melanoma cells is decreased, possibly due to stabilization of mitochondrial permeability by the BCL2 family. The transcription factor NF-κB and the mitogen-activated protein kinase (MAPK) and extracellular-regulated kinase (ERK) 1 and 2 pathways seem to be the principal regulators of the IAP and BCL2 family, respectively. These findings provide insights into resistance of melanoma to apoptosis and provide a framework for therapeutic approaches based on providing pro-apoptotic stimuli, as well as reducing anti-apoptotic mechanisms.
47 schema:genre article
48 schema:isAccessibleForFree false
49 schema:isPartOf N9ee6cf9d03074ddda0888a93d94a22c4
50 Nb735f4d7f9d24dfda2379baf98d2c658
51 sg:journal.1029716
52 schema:keywords BCL2 family
53 DIABLO
54 DIABLO release
55 DNA damage
56 IAP
57 IAP family
58 NF-κB
59 Smac/DIABLO
60 Smac/DIABLO release
61 TNF
62 TRAIL death receptors
63 TRAIL-dependent killing
64 TRAIL-induced apoptosis
65 TRAIL-resistant melanoma cells
66 XIAP levels
67 alternative
68 anti-apoptotic mechanisms
69 apoptosis
70 apoptosis (IAP) family
71 apoptosis-inducing ligand
72 approach
73 cells
74 consequences
75 constitutive expression
76 control
77 damage
78 death pathways
79 death receptor expression
80 death receptors
81 defense mechanisms
82 development
83 development of treatments
84 exposure
85 expression
86 extracellular regulated kinases 1
87 factor NF-κB
88 factor family
89 family
90 findings
91 framework
92 fresh isolates
93 granzyme B
94 host
95 induction
96 induction of p53
97 inhibition
98 inhibitors
99 insights
100 interaction
101 intracellular death pathways
102 isolates
103 killing
104 kinase
105 kinase 1
106 levels
107 ligands
108 main inhibitor
109 mechanism
110 melanoma
111 melanoma cells
112 members
113 mitochondria
114 mitochondrial death pathway
115 mitochondrial permeability
116 mitogen-activated protein kinase
117 most melanoma cells
118 natural defense mechanisms
119 necrosis factor family
120 p53
121 pathway
122 permeability
123 principal regulator
124 pro-apoptotic proteins
125 pro-apoptotic stimuli
126 protein
127 protein kinase
128 receptors
129 regulator
130 release
131 resistance
132 resistance mechanisms
133 resistance of melanoma
134 response
135 stabilization
136 stimuli
137 success
138 therapeutic approaches
139 trails
140 transcription factor NF-κB
141 treatment
142 tumor necrosis factor family
143 upregulation
144 schema:name How melanoma cells evade trail-induced apoptosis
145 schema:pagination 142-150
146 schema:productId N282f46c2ffd84540b5688957036d08a1
147 N370ec15fc08a4bfbacdfc85e1702fe20
148 Nfee2fa4dd6e64424b288aa6ae91972cb
149 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021222128
150 https://doi.org/10.1038/35101078
151 schema:sdDatePublished 2022-10-01T06:31
152 schema:sdLicense https://scigraph.springernature.com/explorer/license/
153 schema:sdPublisher N223b418fe81844d6acfbc2e19ddaebd6
154 schema:url https://doi.org/10.1038/35101078
155 sgo:license sg:explorer/license/
156 sgo:sdDataset articles
157 rdf:type schema:ScholarlyArticle
158 N103dacf83e1d42c7929cb3baf2e01ffe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Tumor Cells, Cultured
160 rdf:type schema:DefinedTerm
161 N140427a3e1a9467fa22d04b9d4bc4a3c rdf:first sg:person.01210116316.18
162 rdf:rest rdf:nil
163 N15cfe3470e684f20ac4016152ec7663b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Fas Ligand Protein
165 rdf:type schema:DefinedTerm
166 N1ea7c674786d45adb6f9befa941c8135 rdf:first sg:person.01073667716.42
167 rdf:rest N140427a3e1a9467fa22d04b9d4bc4a3c
168 N223b418fe81844d6acfbc2e19ddaebd6 schema:name Springer Nature - SN SciGraph project
169 rdf:type schema:Organization
170 N240c4510ca3c4a2ea3c7db4a897c43ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Tumor Necrosis Factor-alpha
172 rdf:type schema:DefinedTerm
173 N25ab614802914ef1a77a956005e70d03 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Neoplasm Proteins
175 rdf:type schema:DefinedTerm
176 N26f76226c7f54577bf9c52ad55dfbc24 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Humans
178 rdf:type schema:DefinedTerm
179 N282f46c2ffd84540b5688957036d08a1 schema:name pubmed_id
180 schema:value 11905805
181 rdf:type schema:PropertyValue
182 N3187e6700efb441cabc0e23bf9640396 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Membrane Glycoproteins
184 rdf:type schema:DefinedTerm
185 N370ec15fc08a4bfbacdfc85e1702fe20 schema:name dimensions_id
186 schema:value pub.1021222128
187 rdf:type schema:PropertyValue
188 N40617c13a25b440fb298b0fd4ec83b12 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Tumor Suppressor Protein p53
190 rdf:type schema:DefinedTerm
191 N452a3979ed1442848c9909c5c4501a57 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Caspase 9
193 rdf:type schema:DefinedTerm
194 N46cf9ce1bd93485e9320fb1513494501 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Animals
196 rdf:type schema:DefinedTerm
197 N54f536ed1439419f814b3cfdf8927d84 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Caspases
199 rdf:type schema:DefinedTerm
200 N56583697bae348669b7dda5ed2a37d7b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Antineoplastic Agents
202 rdf:type schema:DefinedTerm
203 N5dd5904df48a44c7be9550c639746c36 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Cytochrome c Group
205 rdf:type schema:DefinedTerm
206 N62d44a6a6493492ba85ab50e0ec56453 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Macromolecular Substances
208 rdf:type schema:DefinedTerm
209 N646cebc375d84906a31f40b69f3edf01 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
210 schema:name T-Lymphocyte Subsets
211 rdf:type schema:DefinedTerm
212 N7a964cb14e244055a836747353b61bbc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Melanoma
214 rdf:type schema:DefinedTerm
215 N81df16af004c49c4a486654993b7b183 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
216 schema:name Receptors, Tumor Necrosis Factor
217 rdf:type schema:DefinedTerm
218 N8206f0fdfac349d39a6f543d2fd9783d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
219 schema:name Apoptosis
220 rdf:type schema:DefinedTerm
221 N87822fc6b6f34b1dbc1a4f2825bd817c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
222 schema:name Models, Biological
223 rdf:type schema:DefinedTerm
224 N8b070f319e484c738f1b90e1fe9df436 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
225 schema:name Mitochondria
226 rdf:type schema:DefinedTerm
227 N9ee6cf9d03074ddda0888a93d94a22c4 schema:issueNumber 2
228 rdf:type schema:PublicationIssue
229 Nb63ee6f6b47c434680d5085f9ce4f40d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
230 schema:name TNF-Related Apoptosis-Inducing Ligand
231 rdf:type schema:DefinedTerm
232 Nb735f4d7f9d24dfda2379baf98d2c658 schema:volumeNumber 1
233 rdf:type schema:PublicationVolume
234 Nba10fb5036894df6b411d4e1b6e33d77 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
235 schema:name Killer Cells, Natural
236 rdf:type schema:DefinedTerm
237 Nbc84722d4e5844ab9d3cef0a4183904a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
238 schema:name NF-kappa B
239 rdf:type schema:DefinedTerm
240 Nc86ef2e56d6d4b5896676fcf9128800b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
241 schema:name Apoptosis Regulatory Proteins
242 rdf:type schema:DefinedTerm
243 Nddae1e5bfa474b75af7778faae9d8385 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
244 schema:name Signal Transduction
245 rdf:type schema:DefinedTerm
246 Ndeffe4ad6e104bff90017ef887d0bf28 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
247 schema:name DNA Damage
248 rdf:type schema:DefinedTerm
249 Ndfd03d5c47804c6ea56374f89b74dbfe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
250 schema:name Enzyme Activation
251 rdf:type schema:DefinedTerm
252 Ne1b1a3c78a234bec8a663e8c1094290e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
253 schema:name MAP Kinase Signaling System
254 rdf:type schema:DefinedTerm
255 Ne708965c70a0410d837010a3794ead22 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
256 schema:name fas Receptor
257 rdf:type schema:DefinedTerm
258 Nfb8fc4c58e9745cea40ddb3ace36f02c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
259 schema:name Gene Expression Regulation, Neoplastic
260 rdf:type schema:DefinedTerm
261 Nfee2fa4dd6e64424b288aa6ae91972cb schema:name doi
262 schema:value 10.1038/35101078
263 rdf:type schema:PropertyValue
264 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
265 schema:name Medical and Health Sciences
266 rdf:type schema:DefinedTerm
267 sg:journal.1029716 schema:issn 1474-175X
268 1474-1768
269 schema:name Nature Reviews Cancer
270 schema:publisher Springer Nature
271 rdf:type schema:Periodical
272 sg:person.01073667716.42 schema:affiliation grid-institutes:None
273 schema:familyName Hersey
274 schema:givenName Peter
275 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073667716.42
276 rdf:type schema:Person
277 sg:person.01210116316.18 schema:affiliation grid-institutes:None
278 schema:familyName Zhang
279 schema:givenName Xu Dong
280 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210116316.18
281 rdf:type schema:Person
282 sg:pub.10.1007/bf01202725 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033853040
283 https://doi.org/10.1007/bf01202725
284 rdf:type schema:CreativeWork
285 sg:pub.10.1023/a:1009617727938 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045070256
286 https://doi.org/10.1023/a:1009617727938
287 rdf:type schema:CreativeWork
288 sg:pub.10.1038/19709 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044922946
289 https://doi.org/10.1038/19709
290 rdf:type schema:CreativeWork
291 sg:pub.10.1038/22788 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011644064
292 https://doi.org/10.1038/22788
293 rdf:type schema:CreativeWork
294 sg:pub.10.1038/35048073 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053037482
295 https://doi.org/10.1038/35048073
296 rdf:type schema:CreativeWork
297 sg:pub.10.1038/35051606 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052418104
298 https://doi.org/10.1038/35051606
299 rdf:type schema:CreativeWork
300 sg:pub.10.1038/83401 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032285041
301 https://doi.org/10.1038/83401
302 rdf:type schema:CreativeWork
303 sg:pub.10.1038/83416 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047641659
304 https://doi.org/10.1038/83416
305 rdf:type schema:CreativeWork
306 sg:pub.10.1038/nm0298-232 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044054321
307 https://doi.org/10.1038/nm0298-232
308 rdf:type schema:CreativeWork
309 sg:pub.10.1038/sj.leu.2401865 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004336753
310 https://doi.org/10.1038/sj.leu.2401865
311 rdf:type schema:CreativeWork
312 sg:pub.10.1038/sj.onc.1203489 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045600742
313 https://doi.org/10.1038/sj.onc.1203489
314 rdf:type schema:CreativeWork
315 sg:pub.10.1038/sj.onc.1204140 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006396136
316 https://doi.org/10.1038/sj.onc.1204140
317 rdf:type schema:CreativeWork
318 grid-institutes:None schema:alternateName Immunology and Oncology Unit, Room 443, David Maddison Clinical Sciences Building, Cnr King & Watt Streets, 2300, Newcastle, New South Wales, Australia
319 schema:name Immunology and Oncology Unit, Room 443, David Maddison Clinical Sciences Building, Cnr King & Watt Streets, 2300, Newcastle, New South Wales, Australia
320 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...